LFA703

LFA703 is an experimental small molecule inhibitor derived from lovastatin and optimized for inhibition of the integrin lymphocyte function-associated antigen 1 (LFA‑1), also known as integrin alpha-L/beta‑2 or CD11a/CD18. LFA‑1 plays a critical role in leukocyte migration and T cell activation by mediating cell adhesion through binding to intercellular adhesion molecules (ICAMs). By binding to an allosteric site on the alpha-L I domain of LFA‑1—termed the "lovastatin site" or "L-site"—LFA703 induces conformational changes that inhibit its function. This mechanism suggests potential therapeutic value in treating inflammatory diseases by modulating immune cell trafficking and activation. The compound was developed at Novartis Institutes for BioMedical Research[5][9][3].

Other names

288324-06-1(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-8-(2-((2S,4R)-4-hydroxy-1-((5-(hydroxymethyl)-6-methoxy-naphthalenyl)methyl)-6-oxo-piperidinyl)ethyl)-3,7-dimethyl-naphthalenyl (2S)-2-methylbutanoateButanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)...ester